BASLE, Mar. 11, 2008 (Thomson Financial delivered by Newstex) -- Novartis (NYSE:NVS) AG said a Phase III study showed its Femara cancer treatment may make it 63 pct more unlikely that breast cancer will return if it is used anywhere between one year and seven years after finishing tamoxifen therapy.
